ABBV vs PFE
AbbVie Inc. and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | PFE |
|---|---|---|
| Revenue | $61.2B | $62.6B |
| Net income | $4.2B | $7.8B |
| Gross margin | 70.2% | 74.3% |
| Net margin | 6.9% | 12.5% |
| Return on equity | · | 8.9% |
| Diluted EPS | $2.36 | $1.36 |
| Dividend / share | $6.65 | $1.72 |
| Payout ratio | 275.8% | · |
| Free cash flow | $17.8B | $9.1B |
| Equity | $-3.3B | $86.5B |
| Net debt / equity | · | 0.73× |
| Current ratio | 0.67× | 1.16× |
| Revenue CAGR 5y | 6.0% | 8.5% |
| Profit CAGR 5y | −1.7% | −3.2% |
ABBV and PFE book revenue within 15% of each other, and PFE keeps more of each dollar of revenue as profit (12.5% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | PFE |
|---|---|---|
| FY2025 | $61.2B | $62.6B |
| FY2024 | $56.3B | $63.6B |
| FY2023 | $54.3B | $59.6B |
| FY2022 | $58.1B | $101.2B |
| FY2021 | $56.2B | $81.3B |
| FY2020 | $45.8B | $41.7B |
| FY2019 | $33.3B | $40.9B |
| FY2018 | $32.8B | $40.8B |
| FY2017 | $28.2B | $52.5B |
| FY2016 | $25.6B | $52.8B |
Bottom line
| Fiscal year | ABBV | PFE |
|---|---|---|
| FY2025 | $4.2B | $7.8B |
| FY2024 | $4.3B | $8.0B |
| FY2023 | $4.9B | $2.1B |
| FY2022 | $11.8B | $31.4B |
| FY2021 | $11.5B | $22.0B |
| FY2020 | $4.6B | $9.2B |
| FY2019 | $7.9B | $16.0B |
| FY2018 | $5.7B | $11.2B |
| FY2017 | $5.3B | $21.3B |
| FY2016 | $6.0B | $7.2B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$1,419,000,000 | PFE |
| FY2024 | −$7,293,000,000 | PFE |
| FY2023 | −$5,235,000,000 | PFE |
| FY2022 | −$43,121,000,000 | PFE |
| FY2021 | −$25,091,000,000 | PFE |
| FY2020 | +$4,153,000,000 | ABBV |
| FY2019 | −$7,639,000,000 | PFE |
| FY2018 | −$8,072,000,000 | PFE |
| FY2017 | −$24,330,000,000 | PFE |
| FY2016 | −$27,186,000,000 | PFE |
| FY2015 | −$25,992,000,000 | PFE |
| FY2014 | −$29,645,000,000 | PFE |
| FY2013 | −$32,794,000,000 | PFE |
| FY2012 | −$36,277,000,000 | PFE |
| FY2011 | −$43,591,000,000 | PFE |
The higher-revenue side has changed between ABBV and PFE over this period. The gap has narrowed since the earliest year compared.
15 of 19 comparable fiscal years — a year missing data on either side is not counted.
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −5.6 pp | PFE |
| FY2024 | −5.1 pp | PFE |
| FY2023 | +5.3 pp | ABBV |
| FY2022 | −10.6 pp | PFE |
| FY2021 | −6.5 pp | PFE |
| FY2020 | −12.0 pp | PFE |
| FY2019 | −15.6 pp | PFE |
| FY2018 | −10.0 pp | PFE |
| FY2017 | −21.8 pp | PFE |
| FY2016 | +9.5 pp | ABBV |
| FY2015 | +8.2 pp | ABBV |
| FY2014 | −9.6 pp | PFE |
The higher net margin has changed hands between ABBV and PFE over this period.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PFE's net margin has been more volatile than ABBV's over the 12 comparable fiscal years — 10.9 percentage points of standard deviation against 6.4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and PFE over these 12 fiscal years — ABBV led in 3 and PFE in 9.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than PFE's over the 8 comparable fiscal years — 45.0 percentage points of standard deviation against 12.2.
8 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ABBV led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 19 comparable fiscal years — a year missing data on either side is not counted.